TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04883307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Professional development coaching based on a curriculum of positive psychology principles and coaching principles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness resources
Description: Residents in the control group received three emails across the 9 month study period that contained materials related to physician well-being such as personal development and resilience, mindfulness, and work life-integration. Materials included recommended readings, videos, and exercises and were curated by members of the Association of Women Surgeons who were not involved in the coaching program.
Study: NCT00707265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CRM/CD HORIZON® Spinal System
Description: The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/CD HORIZON® Spinal System
Description: The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
Study: NCT03642925

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal replacement diet
Description: Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
Study: NCT03500614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air cleaner use method 1
Description: All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air cleaner use method 2
Description: All interventions in the second cohort will start from the beginning to the end of smog episodes.
Study: NCT01047592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sarcosine
Description: sarcosine, 2 g/d , oral, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sarcosine+ BE
Description: sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo,oral, for 12 weeks
Study: NCT02586025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC Chemotherapy
Description: Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC Chemotherapy
Description: Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
Study: NCT03493243

Intervention type: OTHER
Intervention: Questionnaires
Description: 2-hour clinical observation
Study: NCT03104764

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Labial frenulum removed by scalpel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Labial frenulum removed by Er:YAG laser
Study: NCT04450537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vape Messaging Intervention
Description: Participants will be exposed to 10 vape education messages
Study: NCT01175915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: 1. Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~2. Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~3. No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduning Injection
Description: 1. Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~2. Reduning Injection, 0.5\~15ml, depending on patient's condition, IV per day, or according to the instruction;~3. Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduning Injection plus western therapy
Description: 1. General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~2. Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~3. Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days.
Study: NCT00365391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV, 10 mg/kg, days 1 and 15 in every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally, 150 mg, every day during each cycle.
Study: NCT01702727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-BiTTM game
Description: 30 minutes intervention weekly for 6 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-I-BiTTM game
Description: 30 minutes intervention weekly for 6 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-BiTTM DVD
Description: 30 minutes intervention weekly for 6 weeks.
Study: NCT01406626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigator
Description: Peer navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
Study: NCT05389579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric blanket
Description: After the patients were taken to their own beds after surgery, the researcher covered them with a wool blanket from the top of clavicle to the bottom of their feet, put the sphygmomanometer on the arm without an IV line, positioned the sphygmomanometer so that the instrument panel was on the blanket and measured the patients' blood pressure. Then, the electric blanket was operated at the warm level for the experimental group, and it was turned off and unplugged when their body temperature reached 36.0 °C.
Study: NCT03014674

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized mepolizumab
Description: Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid mepolizumab
Description: Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid mepolizumab
Description: Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled autoinjector
Description: Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefilled Safety Syringe
Description: Single use, disposable safety syringe with a retracting needle guard and locking system.
Study: NCT01096992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
Study: NCT04167501

Intervention type: OTHER
Intervention: biological sample analysis
Description: HPV Prevalence analysis

Intervention type: OTHER
Intervention: biological sample analysis
Description: HPV Prevalence analysis
Study: NCT06239155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-3424
Description: liquid formulation for Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-3424
Description: liquid formulation for Intravenous infusion
Study: NCT02614495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
Study: NCT02191072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
Study: NCT04205630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985
Description: SYD985 powder for concentrate for solution for infusion
Study: NCT01247402

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting balloon angioplasty
Description: 3 microgram Paclitaxel/mm2 on balloon, 60s application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard balloon angioplasty
Description: standard balloon angioplasty
Study: NCT05005780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative peak triggered 100 Hz triplet burst TMS
Description: MagVenture MagPro X100: Ipsilesional negative peak triggered 100 Hz triplet burst TMS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Hz rTMS
Description: MagVenture MagPro X100: Contralesional 1 Hz rTMS.
Study: NCT02434094

Intervention type: BEHAVIORAL
Intervention: eDAPT on-line training program
Description: A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.

Intervention type: BEHAVIORAL
Intervention: eDAPT on-line training program
Description: A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.

Intervention type: BEHAVIORAL
Intervention: eDAPT on-line training program
Description: A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
Study: NCT04928963

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prolon - FMD
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prolon - FMD
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study: NCT04444037

Intervention type: DEVICE
Intervention: OCT-guided PCI
Description: using optical coherence tomography imaging to help PCI procedure
Study: NCT02173548

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01949311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study: NCT03449810

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSE plus MET group A
Description: The Dynamic stabilization exercises will consist of seven exercises, which are aimed to strengthen the lumbar stabilizing muscles. All seven dynamic stabilization exercises will be performed once and always in random order.~The procedure for MET involves voluntary contraction of the participant's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist. In this type of therapy, a participant contracts muscles by pushing against resistance provided by the therapist. The therapist then assists the participant in stretching, strengthening and relaxing those muscles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSE alone group B
Description: The DSE in this arm is the same a described in group A, i.e. it involves seven exercises activities administered randomly at every session of the study intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy treatment group C
Description: In the control group, the participants will receive standard physiotherapy treatment offered for the management of chronic NSLBP patients in Nigeria. Therefore, individuals randomized to this therapeutic group will be treated with classical massage, therapeutic exercises and a combination of interferential therapy and therapeutic ultrasound (INF/UTS) applied to the lumbosacral region.
Study: NCT03281148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided implant insertion group
Description: Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free hand implant insertion group
Description: Implants will be immediately inserted in fresh extraction sockets using free hand technique
Study: NCT01248273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21
Description: The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
Study: NCT03412682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (6 mg)
Description: Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg)
Description: Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine (3,600 mg)
Description: Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
Study: NCT00875004

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin beta

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study: NCT01958632

Intervention type: PROCEDURE
Intervention: Nerve reconstruction

Intervention type: PROCEDURE
Intervention: Nerve reconstruction

Intervention type: PROCEDURE
Intervention: Nerve reconstruction
Study: NCT04517396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fenofibrate/fenofibric acid
Description: The randomized intervention will be fenofibrate (Tricor) at a dose of 145 mg/d or dose-equivalent preparation of fenofibrate or fenofibric acid, for 10 days. In all cases, appropriate dose reductions will be implemented for patients with chronic kidney disease as per the approved preparation label. The intended duration of randomized treatment will be for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control intervention will be a placebo, for 10 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: All participants will otherwise receive usual medical care

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: All participants will otherwise receive usual medical care
Study: NCT00708240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
Study: NCT00455975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study: NCT00999466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8848
Description: Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.